Cornall_lab

[Mukta Deobagkar @MDeobagkar]

Check out our new @SciImmunology paper about the role of DOCK8 in the survival and differentiation of B cells activated by low amounts of antigen: https://t.co/1GleROZMZf
A big shoutout to @CornallLab & @BetterKidneys Thank you @MRC_TIDU @HumanGeneticsOx @NDMOxford @CAMS_COI_Ox

[Waggoner Lab @LabWaggoner]

B cells activated by low amounts of antigen require DOCK8 to acquire survival and differentiation signals via T cell help @SciImmunology @CornallLab
https://t.co/yUNqanwfC0

[Katherine Bull @BetterKidneys]

Exciting postdoc role with our friendly supportive group and @trig_oxford @fgissa. Cell therapy for IgA Nephropathy, part of EU /Horizon consortium. Do you like immunology, kidneys and translational research? Informal enquires / DMs for more info welcome
https://t.co/WQWaany7DE

[Dr Lucy Garner @TheLucyGarner]

I am really excited to announce that our paper (@PKlenermanLab) exploring MAIT cell transcriptional and TCR repertoire diversity in human blood and liver has been released @NatImmunol https://t.co/R1kMgWyLZB #MAITcells

[Immunotherapy Advances Journal @IMTadvances]

Researchers at @DavisLab_Oxford investigate the potential of a new combination #immunotherapy of #nivolumab, a clinically approved #PD1 blocking antibody, & OX108, a #CD200R blocker

Explore their results in mouse models for colorectal & lung #cancer ➡️https://t.co/MV44mMN76W

[Martin Fellermeyer @MFellermeyer]

Very pleased to have my first PhD publication published in @IMTadvances. Using humanised mice we trialled the combination immunotherapy of nivolumab and OX108 (a CD200R blocker) in two tumour models.
@DavisLab_Oxford @CornallLab @MRC_HIU @MRC_WIMM @RDMOxford

[The Journal of Immunology @J_Immunol]

#AuthorChoice: Prolidase deficiency causes spontaneous #Tcell activation and #lupus-like #autoimmunity | from @BetterKidneys @UniofOxford #FreetoRead #ReadTheJI #immunology 👉 https://t.co/DVHAAXawyY

[Katherine Bull @BetterKidneys]

Thanks also to: Tanya Crockford, Aneesha Bhandari, @JessKepple, Jenny Back, Eleanor Cawthorne, Lucie Abeler-Dorner, Adam Laing, Simon Clare, Annie Speak, @David_J_Adams @GordonDougan1 @HaydayLab @MDeobagkar @CornallLab @HumanGeneticsOx @OxfordGenomics

[Katherine Bull @BetterKidneys]

Beautiful T cell single cell analysis by Rose Hodgson shows increased effectors and significant reduction in Ly6c2+ central effector memory.

[Katherine Bull @BetterKidneys]

Chimeric experiments highlight a population of KLRG1+ effector T cells, only observed in association with the autoimmune phenotype.

[Cornall_lab @CornallLab]

We demonstrate that the autoimmune phenotype is associated with a populations of effector CD8 T cells with a phenotype similar to short lived effector cells (SLEC) in viral infection. Read on to find out more: https://t.co/65fGVksE15 @BetterKidneys

[Katherine Bull @BetterKidneys]

Chimeric experiments highlight a population of KLRG1+ effector T cells, only observed in association with the autoimmune phenotype.

[Cornall_lab @CornallLab]

Just published! Prolidase deficient mice have increased incidence of anti-nuclear antibodies, immune complex deposition and altered T cell population composition.
https://t.co/65fGVktbQD

[Katherine Bull @BetterKidneys]

Delighted to share our paper on autoimmunity due to prolidase deficiency. We confirm loss of PEPD results in ANAs and renal immune complex deposition, assoc with T cell activation. https://t.co/w0Qzks0aAx

[Katherine Benjamin @kfbenjamin]

I’m completely thrilled to share our new preprint!

Multiscale topology classifies and quantifies cell types in subcellular spatial transcriptomics

https://t.co/pVkX50HRff

Joint work with Aneesha Bhandari, @BGI_Genomics, Ulrike Tillmann, @BetterKidneys, and @haharrington

1/9

[Katherine Bull @BetterKidneys]

Our lab and @CornallLab giving some thanks

[Katherine Bull @BetterKidneys]

NDRG1 is a target for cancer treatment. But it was also thought to help immune cells 'switch off', so NDRG1 drugs might cause immune over-activity. However we show that although NDRG1 goes up in these immune cells, they don't need NDRG1 to switch off. https://t.co/DCSloSTd1S

[Katherine Bull @BetterKidneys]

Our new paper: NDRG1 is an anti cancer therapeutic target, upregulated in anergic B cells, and previously described as a T cell anergy factor, but we show it is not required for B or T cell tolerance. work led by Rose Hodgson, with @CornallLab @NDMOxford https://t.co/DCSloSTd1S

[Mukta Deobagkar @MDeobagkar]

Fantastic talks and fabulous science at the Oxford Imaging Symposium 2022 today!

[Katherine Bull @BetterKidneys]

Looking forward to applying this to DKD with @JessKepple

[Dr Emily Thornton @emilyethornton]

I dunno, you guys. It seems like the "B is for Boring" slogan might have been a campaign funded by Big B Cell. Those guys are up to some nefarious stuff!
https://t.co/KvePeBcYWW

Anyway, T cells to the rescue!

[Katherine Bull @BetterKidneys]

Congratulations Dr Rose Hodgson! Was an absolute pleasure to have you in the lab, already missing the fancy dress @CornallLab @HumanGeneticsOx